TSE:HLS HLS Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding HLS Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$14.25 -0.25 (-1.72 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's RangeC$14.09Now: C$14.25▼C$14.5950-Day RangeC$14.50MA: C$16.21▼C$17.9352-Week RangeC$14.00Now: C$14.25▼C$25.92Volume12,946 shsAverage Volume40,910 shsMarket CapitalizationC$452.34 millionP/E RatioN/ADividend Yield1.38%BetaN/A ProfileAnalyst RatingsChartCompetitorsDividendEarningsHeadlinesSocial Media HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company is headquartered in Toronto, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for HLS Therapeutics. Previous Next 2.5 Community Rank Outperform VotesHLS Therapeutics has received 12 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHLS Therapeutics has received 12 “underperform” votes. (Add your “underperform” vote.)Community SentimentHLS Therapeutics has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about HLS Therapeutics and other stocks. Vote “Outperform” if you believe HLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHLS Therapeutics has a dividend yield of 1.38%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthHLS Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HLS Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of HLS Therapeutics is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HLS Therapeutics is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHLS Therapeutics has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:HLS Previous Symbol CUSIPN/A CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000Debt Debt-to-Equity Ratio54.91 Current Ratio1.53 Quick Ratio1.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$53.86 million Price / Sales8.40 Cash FlowC$1.06 per share Price / Cash Flow13.44 Book ValueC$5.31 per share Price / Book2.68Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees46 Outstanding Shares31,743,000Market CapC$452.34 million Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable C$14.25 -0.25 (-1.72 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive HLS News and Ratings via Email Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter. HLS Therapeutics (TSE:HLS) Frequently Asked Questions How has HLS Therapeutics' stock price been impacted by COVID-19? HLS Therapeutics' stock was trading at C$18.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HLS stock has decreased by 24.0% and is now trading at C$14.25. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of HLS Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for HLS Therapeutics. When is HLS Therapeutics' next earnings date? HLS Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for HLS Therapeutics. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc (TSE:HLS) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.27. The company had revenue of $17.48 million for the quarter, compared to the consensus estimate of $19.19 million. View HLS Therapeutics' earnings history. How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics? HLS Therapeutics declared a quarterly dividend on Wednesday, August 5th. Investors of record on Friday, October 30th will be given a dividend of 0.05 per share on Tuesday, December 15th. This represents a $0.20 dividend on an annualized basis and a yield of 1.40%. The ex-dividend date is Thursday, October 29th. View HLS Therapeutics' dividend history. Who are some of HLS Therapeutics' key competitors? Some companies that are related to HLS Therapeutics include Aphria (APHA), Aurora Cannabis (ACB), Knight Therapeutics (GUD), Hexo (HEXO), HEXO (HEXO), Amryt Pharma (AMYT), Benchmark (BMK), OrganiGram (OGI), ICC Labs (ICC), Shield Therapeutics (STX), ESSA Pharma (EPI), Green Organic Dutchman (TGOD), cbdMD (YCBD), WeedMD (WMD) and Delta 9 Cannabis (NINE). View all competitors. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial Holdings Ltd Subordinate Voting Shares (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS). Who are HLS Therapeutics' key executives? HLS Therapeutics' management team includes the following people: Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 58)Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder, CEO & Director (Age 62)Mr. Gilbert Godin, Pres & COO (Age 60)Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 48)Mr. Ryan C. Lennox, Gen. Counsel & Corp. Sec. (Age 39) What is HLS Therapeutics' stock symbol? HLS Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HLS." How do I buy shares of HLS Therapeutics? Shares of HLS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is HLS Therapeutics' stock price today? One share of HLS stock can currently be purchased for approximately C$14.25. How big of a company is HLS Therapeutics? HLS Therapeutics has a market capitalization of C$452.34 million and generates C$53.86 million in revenue each year. HLS Therapeutics employs 46 workers across the globe. What is HLS Therapeutics' official website? The official website for HLS Therapeutics is www.hlstherapeutics.com. How can I contact HLS Therapeutics? The company can be reached via phone at 647-495-9000. This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
